| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | Biomarker | disease | BEFREE | We suggest further research into M-ECT and its clinical application in chronic pharmacoresistant schizophrenia. | 30948691 | 2019 | ||||
|
0.060 | Biomarker | disease | BEFREE | The purpose of this systematic review was to examine use of M-ECT in schizophrenia to guide clinical decision making for relapse prevention in schizophrenia. | 29631245 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | Despite controversy, ECT has been recognized as significantly effective for the treatment of mental disorders since 1938, when Cerletti and Bini introduced ECT in clinical psychiatric practice for treatment of schizophrenia. | 29864758 | 2018 | ||||
|
0.060 | Biomarker | disease | BEFREE | The following searches were used in PubMed to obtain the most relevant advances in treating schizophrenia or bipolar disorder with acute agitation and aggression: (agitation, agitated, aggression, aggressive, hostile, hostility, violent, or violence) and (schizophr*, psychosis, psychot*, psychos*, mania, manic, or bipolar) and (*pharmacologic, antipsychotic*, neuroleptic*, antiepileptic*, anti-seizure*, mood stabilizer*, lithium, benzodiazepine*, beta blocker, beta-blocker, alpha2, alpha-2, *histamine*, electroconvulsive, ECT, shock, or transcranial). | 28463343 | 2017 | ||||
|
0.060 | Biomarker | disease | BEFREE | Thirty-two treatment resistant patients with schizophrenia who have been indicated for ECT enrolled in the study. | 27663585 | 2017 | ||||
|
0.060 | Biomarker | disease | BEFREE | This article reviews the indication of ECT for major depression, as well as for other conditions, including catatonia, mania, and acute episodes of schizophrenia. | 28406327 | 2017 |